1 The First Clinical Medical College, Shanxi Medical University, Taiyuan, Shanxi, China 2 Department of Dermatology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China A 42 year-old ...

Dupilumab vs conventional AD therapies had less risk for anxiety, depression, and adjustment and sleep disorders, especially among Black patients. Patients with atopic dermatitis (AD) who were ...

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Bullous Pemphigoid. According to GlobalData, Phase III drugs for Bullous Pemphigoid does not have ...

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase II drugs for Systemic Sclerosis ...

The success of dupilumab, marketed by Sanofi under the name Dupixent, is evident in its remarkable $13 billion global sales achievement in 2024, marking a significant milestone for the company.